Co-Inventors
Purcell, Robert
Blaney, Joseph
Applications
Vaccines
Therapeutics
Diagnostics
Research Products
Research Equipment
Antibodies
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.
Commercial Applications
These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies.
Competitive Advantages
This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease.
